NSPR InspireMD

InspireMD, Inc. Appoints Patrick Jamnik as Vice President of Business Development and Strategic Initiatives and Reports Inducement Grants Under NYSE American Company Guide §711(a)

InspireMD, Inc. Appoints Patrick Jamnik as Vice President of Business Development and Strategic Initiatives and Reports Inducement Grants Under NYSE American Company Guide §711(a)
EN
06/10/2020

Underlying

NSPRInspireMD

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on InspireMD

 PRESS RELEASE
Free
NSPR INSPIREMD

InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent Syste...

InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke MIAMI, June 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (the “Company”) (Nasdaq: NSPR), developer of the CGuard Prime Carotid Stent System for the prevention of stroke, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket application (PMA) approval of the CGuard Prime Carotid Stent System in the United States. The PMA approval is backed by best-in-class evidence from the Company’s C-GUARDIANS pivotal trial, first presented at the Leipzig Interventional...

June 24, 2025 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevent...

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke MIAMI, June 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the company has received CE Mark approval under the European Medical Device Regulation (MDR) for the CGuard® Prime EPS. CGuard® Prime was developed incorporating extensive user feedback and optimizes deliverability and deployment of the proven CGuard stent. With its proprietary MicroNet™...

June 13, 2025 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD

InspireMD Announces Appointment of Michael Lawless as Chief Financial ...

InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) MIAMI, June 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced the appointment of Michael Lawless, an industry veteran, as Chief Financial Officer, effective on or prior to June 30, 2025 (the “Effective Date”). On the Effective Date, Mr. Lawless will succeed Craig Shore, who has served as Chief Financial...

June 3, 2025 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD

InspireMD Reports First Quarter 2025 Financial Results

InspireMD Reports First Quarter 2025 Financial Results Management to host investor conference call today, May 9th, at 8:30am ET MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the first quarter ended March 31, 2025. Business Highlights: Continued engagement with the U.S. Food and Drug Administration (FDA) on the Premarket Approval (PMA) application for the CGuard Prime carotid stent...

May 9, 2025 1 EN
 PRESS RELEASE
Free
NSPR INSPIREMD

InspireMD to Present at Upcoming Bank of America 2025 Healthcare Confe...

InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference MIAMI, April 30, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced management will present at the Bank of America 2025 Healthcare Conference on Wednesday, May 14, 2025, at 1:15PM Eastern Time / 10:15AM Pacific Time. A live audio webcast and replay of the presentation may be accessed for 90 days on the “News & Events” section of the company’s website at: About Inspi...

April 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch